Status:
TERMINATED
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
Lead Sponsor:
Daiichi Sankyo
Conditions:
Stroke
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.
Detailed Description
The primary objective of the study is to determine the efficacy of a 72 hour infusion of SUN N4057 (piclozotan) in subjects with clinical findings of an acute ischemic stroke and a magnetic resonance ...
Eligibility Criteria
Inclusion
- General inclusion criteria:
- Males or females \>= 18 and \<= 85 years of age at randomization. Female subjects must be either:
- Surgically sterile;
- Postmenopausal for at least 1 year; or
- Non-pregnant, confirmed by a serum pregnancy test, and using a method of birth control that is acceptable to the investigator.
- Neurological examination demonstrating localizing cortical signs
- Receipt of study drug less than 6 hours (50% of subjects) or between 6 and 9 hours, inclusive, (50% of subjects) after the onset of symptoms (for un-witnessed stroke, last time seen in normal state or at bedtime for un-witnessed stroke during sleep)
- Signed informed consent from subject or legally acceptable representative
- NIHSS score of 6 - 22, inclusive, or at least 2 on the aphasia item of the NIHSS with a location of MRI findings consistent with aphasia
- MRI-determined inclusion criteria:
- Acute ischemic stroke with substantial cortical involvement in the middle cerebral artery (MCA) distribution, as verified by the Screening DWI abnormality and/or Screening PWI abnormality. (Note: white matter involvement, in addition to cortex, is not an exclusion.)
Exclusion
- General exclusion criteria:
- Two or more of the following:
- Reduced level of consciousness (score \>= 2 on NIHSS Q1a)
- Forced eye deviation or total gaze paresis (score of 2 on NIHSS Q2)
- Dense hemiplegia (no movement) of upper and lower extremities (score of 4 on NIHSS Q5 regarding motor arm and a score of 4 on NIHSS Q6 regarding motor leg)
- Pre-stroke modified Rankin score \>= 2 at Screening
- Rapid neurological improvement from Screening up to the start of drug infusion
- Persistent systolic blood pressure (SBP) \> 220 mmHg and/or diastolic blood pressure (DBP) \> 120 mmHg (confirmed by at least three readings taken at least 3 minutes apart) prior to randomization. If subsequent readings are consistently below these levels, either spontaneously or following mild antihypertensive therapy, subject may be enrolled.
- MRI-determined exclusion criteria:
- Intracranial hemorrhage as verified by Screening MRI. (Note: intracranial hemorrhage on pre-screen computerized tomography \[CT\] scan also excludes subject.)
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00272909
Start Date
September 1 2004
End Date
January 1 2007
Last Update
October 20 2015
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Stroke Network
Los Angeles, California, United States, 90024
2
San Francisco Clinical Research Center
San Francisco, California, United States, 94109
3
The Stroke Center at Hartford Hospital
Hartford, Connecticut, United States, 06102
4
Lakeland Regional Medical Center
Lakeland, Florida, United States, 33805